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Background: Uveal melanoma is an aggressive cancer which has a high percentage metastasizing to the liver, with
a worse prognosis. Identification of patients at high risk of metastases may provide information for early detection
of metastases and treatment.
Methods: Expression profiling of ocular tumor tissues from 46 liver metastatic uveal melanoma samples and 45
non-metastatic uveal melanoma samples were got from GEO database. Bioinformatic analyses such as the Gene
Oncology and Kyoto Encyclopedia of Genes and Genomes were used to identify genes and pathways specifically
associated with liver metastases of the uveal melanoma.
Results: A total of 1138 probes were differentially expressed in two group samples. All differential gene interactions
in the Signal-Net were analyzed. Of them, 768 probes were up-regulated and 370 down-regulated. They mainly
participated in 125 GO terms and 16 pathways. Of the genes differentially expressed between two group cancers,
HTR2B, CHL1, the ZNF family, YWHAZ and FYN were the most significantly altered.
Conclusions: Bioinformatics may help excavate and analyze large amounts of data in microarrays by means of
rigorous experimental planning, scientific statistical analysis and collection of complete data about liver metastases
of uveal melanoma patients. In the present study, a novel differential gene expression pattern was constructed and
advanced study will provide new targets for diagnosis and mechanism of uveal melanoma liver metastases.
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Uveal melanoma is the most common primary intracel-
lular tumor in adults with an estimated 5-year survival
rate of 50%-70% [1]. About 50% of patients develop
metastases within a median of 36 months, mostly to the
liver, with a median survival of 6 months after metasta-
ses [2]. It seems important to identify high-risk patients
at the time of the initial diagnosis for early detection and
treatment of metastatic disease or for the administration
of adjuvant therapy. Several clinical and histopatho-
logical features have been correlated with survival, in-
cluding patient age (>60), anterior location of the tumor,* Correspondence: leichen51@hotmail.com; zhangjh_0312@aliyun.com
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reproduction in any medium, provided the ortumor cell histology, largest diameter of the tumor, mi-
totic activity, and chromosome 3 monosomy. The most
frequent chromosomal imbalances in uveal melanoma
are loss of chromosome 3 and gains of 8q and 6p [3].
Despite the improvements in diagnosis and the devel-
opment of more effective local therapies for primary
tumors, the rate of metastatic death remains unchanged.
Unfortunately, once uveal melanoma has spread to dis-
tant organs, the disease is largely resistant to currently
available therapies [4]. Nowadays, many new prognostic
factors such as Cytological Features, Standard Karyotyping,
Fluorescence in situ Hybridization, Centromeric Probes,
Single Nucleotide Polymorphism and Gene Expression
Profiling were investigated. Following the technique ad-
vance and lower expense of gene expression microarray, it
has become a useful tool for studying the development and
progression of tumors owing to its high throughout, newLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Clinicopathologic characteristics of uveal
melanoma patients
Characteristic Non-metastatic
patients (n = 45)
Liver metastatic
patients (n = 46)
Mean age, years 60.96 ± 14.4 63.17 ± 10.21
Mean primary tumor thickness
(mm)
10.13 ± 2.97 11.45 ± 2.76
Mean tumor largest diameter
(mm)
14.64 ± 4.14 15.08 ± 4.01





















Partial monosomy 2 3
NA 2 6
Clinicopathologic characteristics of uveal melanoma patients got from the
published article and each GSM information. NA, not available.
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could be found.
Several gene expression profiling studies have identi-
fied two molecular classes strongly associated with meta-
static risk [5-7]. Hepatocyte growth factor/scatter factor
(HGF) [8-10], Insulin-like growth factor [11] and Stem
cell factor [12-14] receptors have been involved in meta-
static progression of uveal melanoma. In addition, the
chemokine receptor CXCR4 was recently related to
liver homing of human uveal melanoma metastatic cells
[15,16]. However, little is known about the core genes
and their potential mechanisms in liver metastases. The
present study made use of bioinformatics method to
analyze the data obtained from two public available data-
sets in combination with the clinical data about metasta-
ses of uveal melanoma patients in attempt to investigate
the liver metastases-related genes. The different gene
ontology and pathways would indicate the most import-
ant mechanisms and candidate genes in the process of
liver metastases, and helpful in working out more spe-
cific and individualized target treatment regimens ac-
cording to genetic characteristics of individual patients.
Methods
Tissue samples and clinical data
Tissue samples were obtained from two datasets in total
92 uveal melanomas after enucleation surgery upon ap-
proval of the institutional bioethics board. The patients
in the two datasets were composed of 63 and 29 sam-
ples, respectively [17,18]. All the samples were per-
formed on Affymetrix Human Genome U133 Plus 2.0
Array. Both of two data series were accessible at NCBI
GEO database, accession GSE22138 and GSE27831. Clin-
ical, pathological, and molecular features of the tumors
are presented in Table 1.
Significant differential gene analysis
All 92 tumors in two datasets were pooled and reanalyzed
on Affymetrix Expression Console Software (Version 1.1).
MAS5 was used to normalize the original data. One sam-
ple was removed after the normalized data filtered with
Pearson’s Correlation (Additional file 1: Figure S1), and
the remaining 91 samples were renormalized. Genes were
standardized and interpreted functionally before compari-
son. Using t-test, SAM or RVM mode and the tumors
with no metastases as the control group, the P value and
the fold change were calculated for each differentially
expressed gene. With a threshold of P value < 0.05 or
FDR value < 0.05 and fold change > =1.5, related genes
were picked out and the venn diagram was showed in
Additional file 2: Figure S2. Based on our sample size and
previous study [19], t-test result was chose for further
analyze. Unsupervised hierarchical clustering was per-
formed with Cluster using Pearson’s correlation distancemetric and average linkage followed by visualization in
Treeview [20].
Gene ontology (GO) analysis
Based on Gene Ontology Database (http://www.geneontology.
org/), the significant level of GOs of the liver metastases-
related differentially expressed genes was analyzed by
two-side Fisher’s exact test and χ2 test using DAVID
(http://david.abcc.ncifcrf.gov/home.jsp) analysis [21]. The
differential expression genes were analyzed independently
according to up- and down-regulation of these genes. We
computed P-values for all the differential expression genes
in all GO categories, and the threshold of significance was
defined as P-value < 0.05.
Figure 1 (See legend on next page.)
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Figure 1 Unsupervised classification of uveal melanoma samples based on gene expression profiling. Classification of 91 uveal melanoma
samples using the 1138-probe sets identified as differentially expressed between the 46 liver metastatic samples and the 45 non-metastatic samples.
Expression data are depicted as a data matrix where each row represents a gene and each column represents a sample. Expression levels are depicted
according to the color scale shown at the top. Red and green indicate expression levels, respectively, above and below the median. The magnitude of
deviation from the median is represented by the color saturation.
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Based on KEGG (http://www.genome.jp/kegg/) database,
the significant level of pathways of the liver metastases-
related differentially expressed genes was analyzed by
Pathway-Express [22,23]. Significant differences from the
expected were calculated with a two-sided binomial
distribution. The numbers of genes corresponding to
each pathway category among the differentially expressed
genes was tallied and compared with the number of genes
expected for each pathway category based on their repre-
sentation on the Affymetrix Human Genome U133 plus
2.0 array. All signaling pathways were analyzed for the
significance level, using gamma P < 0.05 as the threshold.Table 2 Most obviously dysregulated genes sorted by












NEURL1B 1.67 × 10-9 51.47 88.42 1.72
EXT1 2.82 × 10-9 203.15 362.35 1.78
DERL1 4.89 × 10-9 178.31 412.54 2.31
GALNTL4 1.22 × 10-8 57.44 128.49 2.24
MR1 1.41 × 10-8 60.08 98.74 1.64
DDX39 3.31 × 10-8 347.31 556.46 1.60
HTR2B 3.49 × 10-8 41.04 574.49 14.00
RAB2A 5.29 × 10-8 363.13 741.99 2.04
C10orf26 6.68 × 10-8 376.40 569.30 1.51
GJC1 7.39 × 10-8 25.95 75.05 2.89
CHL1 8.99 × 10-8 80.84 17.12 0.21
ZNF33B 2.17 × 10-8 41.91 21.24 0.51
OVOS2 2.44 × 10-8 857.96 185.87 0.22
EIF1B 3.35 × 10-7 1008.84 567.87 0.56
PHLDA1 5.22 × 10-7 370.24 134.93 0.36
PLSCR4 5.34 × 10-7 114.83 53.41 0.47
MEGF10 8.38 × 10-7 165.39 26.05 0.16
ZNF415 1.19 × 10-6 37.03 13.91 0.38
ZNF667 1.25 × 10-6 34.08 16.02 0.47
MEGF10 1.66 × 10-6 22.24 10.21 0.46
Most obviously dysregulated genes sorted by p value in liver metastatic uveal
melanoma (n = 45) vs. non-metastatic tumors (n = 46).Signal-net analysis
Using java that allows users to build and analyze mo-
lecular networks, network maps were constructed. For
instance, if there is confirmative evidence that two genes
interact with each other, an interaction edge is assigned
between the two genes. The considered evidence is the
source of the interaction database from KEGG. Net-
works are stored and presented as graphs, where nodes
are mainly genes (protein, compound, etc.) and edges
represent relation types between the nodes, e.g. activa-
tion or phosphorylation. The graph nature of Networks
raised our interest to investigate them with powerful
tools implemented in R.
Data analysis
Numerical data were presented as means and standard
deviation (± SD). Differences between means were ana-
lyzed using Student’s t test. All statistical analyses were
performed using SPSS11.0 software (Chicago, IL).
Results
Clinical characteristics of the two group samples
Comparing with the non-metastases uveal melanoma
samples, the liver metastases group has no differencesTable 3 Most obviously dysregulated genes with fold
change absolute value > 3 in liver Metastatic Uveal
Melanoma compare to non-metastatic tumors
Gene
symbol








HTR2B 3.49 × 10-8 5.36 9.17 14.00
PPM1K 2.96 × 10-6 7.67 9.39 3.30
SSX4 1.03 × 10-4 5.65 7.28 3.09
PTGER4 3.01 × 10-3 6.75 8.36 3.06
MEGF10 8.38 × 10-7 7.37 4.70 0.16
SYNPR 1.25 × 10-5 9.15 6.83 0.20
CHL1 8.99 × 10-8 6.34 4.10 0.21
OVOS2 2.44 × 10-7 9.74 7.54 0.22
LOC100128252 5.70 × 10-6 7.54 5.55 0.25
MPPED2 5.58 × 10-6 6.28 4.40 0.27
CNTN3 1.37 × 10-5 5.40 3.60 0.29
PCDH20 2.94 × 10-3 5.82 4.07 0.30
Most obviously dysregulated genes with fold change absolute value > 3 in
liver metastatic uveal melanoma (n = 45) vs. non-metastatic tumors (n = 46).




Germ cell programmed cell death 32.29 2.80 × 10-3
Developmental programmed cell death 19.37 8.95 × 10-3
Protein retention in ER lumen 13.84 1.80 × 10-2
Germ cell migration 13.45 3.65 × 10-4
Melanocyte differentiation 9.22 8.27 × 10-3
Mitotic cell cycle spindle assembly
checkpoint
8.81 4.36 × 10-2
Negative regulation of mitotic metaphase/
anaphase transition
8.81 4.36 × 10-2
Pigmentation during development 8.69 1.14 × 10-4
Pigment cell differentiation 8.61 1.01 × 10-2
Antigen processing and presentation of
peptide antigen via MHC class I
7.60 1.44 × 10-2
Positive regulation of calcium ion
transport into cytosol
6.46 2.26 × 10-2
Regulation of calcium ion transport
into cytosol
5.57 1.16 × 10-2
T cell proliferation 4.78 4.95 × 10-2
Regulation of transforming growth factor
beta receptor signaling pathway
4.14 3.15 × 10-2
Positive regulation of homeostatic process 4.04 3.42 × 10-2
Response to vitamin A 3.84 4.00 × 10-2
Pigmentation 3.83 9.50 × 10-3
Mitotic cell cycle checkpoint 3.75 4.30 × 10-2
Regulation of calcium ion transport 3.74 5.31 × 10-3
Extracellular matrix organization 3.73 3.63 × 10-4
Alcohol biosynthetic process 3.67 4.62 × 10-2
Regulation of metal ion transport 3.59 3.49 × 10-3
Leukocyte mediated immunity 3.38 5.04 × 10-3
Cellular response to insulin stimulus 3.32 1.83 × 10-2
Regulation of ion transport 3.26 3.51 × 10-3
Lymphocyte mediated immunity 3.23 2.09 × 10-2
Response to organic cyclic substance 3.20 1.30 × 10-3
Response to toxin 3.18 3.98 × 10-2
Double-strand break repair 3.12 4.23 × 10-2
Sphingolipid metabolic process 3.01 2.82 × 10-2
Response to molecule of bacterial origin 3.00 1.70 × 10-2
Adaptive immune response 2.94 3.16 × 10-2
Response to lipopolysaccharide 2.94 3.16 × 10-2
Adaptive immune response based on
somatic recombination of immune
receptors built from immunoglobulin
superfamily domains
2.94 3.16 × 10-2
Cellular response to hormone stimulus 2.91 2.77 × 10-3
Response to insulin stimulus 2.91 1.22 × 10-2
Membrane lipid metabolic process 2.79 3.91 × 10-2
Activation of MAPK activity 2.76 4.11 × 10-2
Table 4 Different gene significant upregulated GO
(Continued)
Immune effector process 2.65 8.66 × 10-3
Protein processing 2.59 2.27 × 10-2
Extracellular structure organization 2.57 4.72 × 10-3
Response to oxidative stress 2.56 4.95 × 10-3
Positive regulation of MAP kinase activity 2.53 3.86 × 10-2
Regulation of MAP kinase activity 2.52 1.21 × 102
Amine transport 2.46 2.99 × 10-2
Camera-type eye development 2.41 4.79 × 10-2
Carbohydrate biosynthetic process 2.41 4.79 × 10-2
Protein oligomerization 2.41 7.85 × 10-3
Protein maturation 2.38 3.54 × 10-2
Nucleotide biosynthetic process 2.26 1.29 × 102
Nucleobase, nucleoside and
nucleotide biosynthetic process
2.17 1.69 × 10-2
Nucleobase, nucleoside, nucleotide
and nucleic acid biosynthetic process
2.17 1.69 × 10-2
Cell proliferation 2.15 2.12 × 10-4
Muscle organ development 2.14 1.41 × 102
Regulation of neurogenesis 2.14 3.34 × 10-2
Skeletal system development 2.13 2.21 × 10-3
Response to peptide hormone stimulus 2.10 4.96 × 10-2
Transmembrane receptor protein tyrosine
kinase signaling pathway
2.02 2.20 × 10-2
Regulation of nervous
system development
2.02 3.63 × 10-2
Nitrogen compound
biosynthetic process
1.99 5.98 × 10-3
Enzyme linked receptor protein signaling
pathway
1.98 4.86 × 10-3
Response to drug 1.94 3.62 × 10-2
Blood vessel development 1.84 4.11 × 10-2
Response to DNA damage stimulus 1.82 1.20 × 10-2
Induction of apoptosis 1.82 2.14 × 10-2
Induction of programmed cell death 1.81 2.19 × 10-2
Positive regulation of apoptosis 1.80 7.74 × 10-3
Vasculature development 1.80 4.83 × 10-2
Positive regulation of programmed cell death 1.79 8.09 × 10-3
Positive regulation of cell death 1.78 8.74 × 10-3
M phase 1.77 2.70 × 10-2
Response to hormone stimulus 1.76 1.98 × 10-2
Response to endogenous stimulus 1.75 1.46 × 10-2
Cell cycle phase 1.72 1.82 × 10-2
Response to abiotic stimulus 1.67 3.73 × 10-2
Protein kinase cascade 1.66 3.89 × 10-2
Cellular response to stress 1.65 9.67 × 10-3
Response to organic substance 1.61 5.45 × 10-3
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Table 4 Different gene significant upregulated GO
(Continued)
Phosphorylation 1.57 5.41 × 10-3
Oxidation reduction 1.57 1.51 × 10-2
Phosphate metabolic process 1.56 2.49 × 10-3
Phosphorus metabolic process 1.56 2.49 × 10-3
Cell cycle process 1.54 2.79 × 10-2
Protein amino acid phosphorylation 1.50 2.49 × 10-2
Immune response 1.50 2.35 × 10-2
Regulation of cell proliferation 1.44 3.02 × 10-2
Regulation of programmed cell death 1.43 2.88 × 10-2
Regulation of cell death 1.43 3.01 × 10-2
Regulation of apoptosis 1.41 3.91 × 10-2




Calcium-dependent cell-cell adhesion 9.49 3.90 × 10-2
Response to acid 9.09 4.22 × 10-2
Embryonic skeletal system development 5.67 4.04 × 10-3
Response to vitamin 5.51 1.26 × 10-2
Regulation of cell shape 5.39 3.75 × 10-2
Regulation of Rho protein signal
transduction
5.14 2.36 × 10-3
Pigmentation 4.93 4.68 × 10-2
Cartilage development 4.91 1.85 × 10-2
Skeletal system morphogenesis 3.90 1.88 × 10-2
Regulation of cell morphogenesis 3.89 9.22 × 10-3
Translational elongation 3.60 4.97 × 10-2
Muscle tissue development 3.49 2.85 × 10-2
Zhang et al. BMC Medical Genetics 2014, 15:29 Page 6 of 10
http://www.biomedcentral.com/1471-2350/15/29on patients’ age, gender or tumor diameter. The tumor
thickness value was much larger in the liver metastases
samples than in the non-metastases group. Though the
tumor location, extrascleral extension, tumor cell type
and chromosome 3 data were incomplete, the first two
appeared no differences while the mixed subtype tumor
and chromosome 3 monosomy showed positive correl-
ation with liver metastases of uveal melanoma (Table 1).Homophilic cell adhesion 3.33 3.40 × 10-2
Regulation of neuron differentiation 3.28 3.59 × 10-2
Embryonic organ morphogenesis 3.28 3.59 × 10-2
Regulation of cell development 3.19 7.23 × 10-3
Regulation of Ras protein signal transduction 3.12 8.25 × 10-3
Muscle organ development 3.10 8.54 × 10-3
Regulation of neurogenesis 3.07 2.66 × 10-2
Response to drug 3.03 9.75 × 10-3
Embryonic organ development 2.96 3.09 × 10-2
Regulation of small GTPase mediated signal
transduction
2.89 7.88 × 10-3
Skeletal system development 2.74 4.38 × 10-3
Heart development 2.71 2.85 × 10-2
-2Liver metastases-related differential expression genes
Using liver metastases as the demarcation, genes of non-
metastases and liver metastases groups were compared
and 1138 statistically significant differential expression
probes were obtained. Of them, 768 probes were up-
regulated in the non-metastases samples and 370 were
down-regulated. Hierarchical clustering showed systematic
variations in the expression of genes between the two
groups (Figure 1). The results demonstrated these dif-
ferential probes could clearly separate the two groups
from the whole samples and have good consistency in
the group. Different genes with the most obvious p value
and fold change between the liver metastases and non-
metastases group were listed (Tables 2 and 3).Regulation of nervous system development 2.65 4.85 × 10
Cell-cell adhesion 2.64 1.37 × 10-2
Negative regulation of cell proliferation 2.62 4.07 × 10-3
Cell adhesion 2.60 2.99 × 10-5
Biological adhesion 2.59 3.06 × 10-5
Actin cytoskeleton organization 2.57 3.59 × 10-2
Actin filament-based process 2.41 4.79 × 10-2
Chordate embryonic development 2.20 3.87 × 10-2
Embryonic development ending in birth or
egg hatching
2.18 4.03 × 10-2
Cytoskeleton organization 2.17 1.68 × 10-2
Regulation of cell proliferation 2.03 2.54 × 10-3
Response to organic substance 1.71 3.85 × 10-2Significant GOs
GOs of the differential expression genes were statistically
analyzed. It was found that the differential expression
genes obtained from the Microarray mainly participated
in 125 significant GOs. According to the enrichment list,
the up-regulated differential expression genes mainly
participated in 89 GOs including germ cell programmed
cell death, developmental programmed cell death, germ
cell migration, melanocyte differentiation (Table 4), and
the down-regulated differential expression genes mainly
participated in 36 GOs including embryonic skeletal
system development, regulation of Rho protein signal
transduction, regulation of cell morphogenesis (Table 5).Significant Pathways
The pathways of liver metastatic uveal melanoma samples
were analyzed according to the functions and interactions
of the differential genes. By using Pathway-Express which
contains both the up- and down- regulated differential
genes in its analysis and the threshold of significance
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nificant pathways were found. Many signaling pathways
had been verified to relate to cell migration and inva-
sion, including Phosphatidylinositol signaling system,
Gap junction, Adherens junction (Figure 2).
Signal-network
According to the literature and experimental records in
the databases, a diagram of the gene interaction network
was drawn up based on the genes differentially expressed
between liver metastases and non-metastases uveal mel-
anoma (Figure 3). The total number of genes in the net-
work was 297, and the particular relationships between
them were listed (Additional file 3). In the network,
cycle nodes represent genes, and edges between two
nodes represent interactions between genes, which were
quantified by degree. Degrees within the network which
describe the number of single gene that regulates other
genes represent the size of the cycle node. The higher
the degree, the more central the gene occurs within the
network. There were many more genes upregulated in-
volved in the Signal-Net analysis, of which YWHAZ,
PRKDC, and ESR1 were the three main overexpressed
genes, while the three main underexpressed genes were
FYN, TIAM1 and GNAI1.
Discussion
The present study followed up microarray-based 91
uveal melanoma patients, of whom patients were not
significantly different in age, gender and tumor diameter.
More than 1100 probes were differentially dysregulated
in liver metastases uveal melanoma in this study. Based
on sorting the different genes by p value and fold
change, numbers of genes with the largest difference in-
dividually were carried out. HTR2B is a type of serotonin
receptor with both the extremely significant p value and
the largest upregulated fold change in the two groups.Figure 2 Histogram of signal pathways those were significantly
different in liver metastatic and non-metastatic uveal melanoma
showing. X axis, negative logarithm of the P value (−LgP); Y axis, the
name of the pathway. The larger the -LgP, the smaller the P value.Soll et al. had found serotonin can promote tumor
growth in hepatocellular cancer [24] and this maybe an
effective hint to us. CHL1 is a cell adhesion molecule
with homology to L1CAM involved in the regulation of
cell adhesion and migration. Current study had sup-
ported a significant role for CHL1 gene in the growth,
migration and invasion of human cervical cancer cells
[25]. MEGF10 and OVOS2 have the largest downregu-
lated fold change and a significant p value. It is still lack
of information about their roles both in tumor and oph-
thalmology. Zinc finger proteins are among the most
abundant proteins which were involved in transcrip-
tional activation, apoptosis regulation and protein fold-
ing. Some zinc finger protein had been detected related
to melanoma [26]. However, there have been no reports
of a differential expression of ZNF family members in
liver metastases uveal melanoma. Comparing with the
original papers of the expression microarray, we found
PTP4A3/PRL3 still has significant difference while SDCBP
dropped out with too little fold change. In our opinion,
this is caused by the enlargement of sample number which
may impact larger in the previously smaller sample group
for GSE27831 has only 29 samples. For the sample
number we integrate here is not so small, though these
genes were still lack of information about their impact
on uveal melanoma liver metastases, we have the rea-
son to focus on them in further investigation.
The GO is widely recognized as the premier tool for
the organization and functional annotation of molecular
aspect [27]. GO-analysis was used to interpret each GO
of differential expressed gene and analyzed it statistically.
By using the criteria of P < 0.05, we obtained the signifi-
cant GOs and genes involved in them. Guo et al. used
GO-analysis to analyze miRNA microarray and found
that miR-15b and miR-16 may be indispensable for
apoptosis by targeting Bcl-2 [28]. GO terms about pro-
grammed cell death plays an important role in liver
metastases, many studies had reported proteins such as
TRAIL and TGF-β1 involved in cell apoptosis also af-
fected cancer cell metastases [29,30]. Ion transport re-
lated genes is little investigated in cancer cell metastases,
but recently Lee et al. found monoamine carboxylate
transporters could impact colon fibrosarcoma cell mi-
gration through regulating extracellular pH value [31].
This may be a new way investigating uveal melanoma
liver metastases. Also the structural changes of intracel-
lular organelles and cytoskeletal would of course act on
cell migration and invasion. According to our results,
programmed cell death, ion transport and cytoskeletal
would affect cell environment to play roles in liver me-
tastases. Furthermore, other biological process may also
have their effects in uveal melanoma distant metastases.
Pathways analysis can show the distinct biological
process and find significant pathways that differential
Figure 3 Signal transduction networks of liver metastatic related genes. Circle represents genes, red circle represents the upregulated gene,
and blue circle represents the downregulated gene. Arrow represents the activation of (a); straight line represents combine; dotted line represents
indirect effects; a represents activation; ex represents gene expression; b represents binding; ind represents indirect effects; inh represents inhibition;
u represents ubiquination. For the most interesting nodes, the fold change and p value were added to the YWHAC and FYN.
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have a comprehensive understanding about interactions
of genes, functions that they participate in and relations
between up- and down-stream, and obtain genes in-
volved in these significant pathways. Appearance of
pathways about cell junction, melanogenesis and calcium
signaling pathway confirm their concordance with GO
terms and their critical role in liver metastases. Numer-
ous studies had proved PI3K/Akt signaling pathway
which belongs to phosphatidylinositol signaling pathway
participated in different cancers’ liver metastases [32-34].
Holder et al. had reported gap junction may affect cancer
metastases since connections are made between the pri-
mary tumor cells and foreign host cells at the secondary
metastatic site [35]. Found of epimorphin activating focaladhesion kinase/extracellular signal-regulated kinase/matrix
metalloproteinase-9 axis to promote hepatocellular car-
cinoma invasion and metastases verified focal adhesion
and ECM-receptor interaction’s role in liver metastases.
For this, we have reasons to believe the other seemingly
irrelevant pathways would have their functions in uveal
melanoma metastases.
Investigating genes involved in significant GOs and
pathways, 297 genes in common were found that may
affect the liver metastases of uveal melanoma patients.
YWHAZ and FYN were identified as key genes in uveal
melanoma liver metastases and play crucial roles in cell
proliferation, which may be related to the higher inci-
dence of metastases in uveal melanoma. YWHAZ previ-
ously was thought as a reference gene in many cell lines,
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beta-Catenin Axis and promote Epithelial-Mesenchymal
Transition and Lung Cancer Metastases [36,37]. FYN
was a member of the Src family of kinases and though
lack of data about its role in uveal melanoma, it partici-
pated in many cancers metastases through different
pathways [38-40]. Based on these data, further studies of
these genes’ expression and the protein functions of
HTR2B, CHL1, the ZNF family, YWHAZ and FYN
need to be performed in more samples using reverse
transcriptase-polymerase chain reaction and western
blotting; moreover, for the GO and pathway findings
are based on the currently known database, the regula-
tion of identified genes and protein functions may have
some other ways.
The above results all suggest that differences in gene
expression exist between liver metastases and non liver
metastases uveal melanoma. These genes encode pro-
teins involved in different GOs and signal pathways, the
disruption of which can promote cancer metastases.
Several genes, such as HTR2B, CHL1, the ZNF family,
YWHAZ and FYN provide potential candidates for dis-
tinguishing between uveal melanoma whether contain
liver metastases in the future. This distinction will aid in
the diagnosis and prevention of uveal melanoma liver
metastases, based on their different features. Therefore,
our results may provide important referential merit for
clinical investigation. Nevertheless, the genes and the
related GOs and pathways identified here are required
to be further dissected and confirmed in more patient
samples by other clinic-related studies.
Conclusion
Bioinformatics may help excavate and analyze large
amounts of data in microarrays by means of rigorous
experimental planning, scientific statistical analysis and
collection of complete data about liver metastases of
uveal melanoma patients. In the present study, a novel
differential gene expression pattern was constructed and
advanced study will provide new targets for diagnosis
and mechanism of uveal melanoma liver metastases.
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